Andre Rogatko
Overview
Explore the profile of Andre Rogatko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tighiouart M, Rogatko A
Entropy (Basel)
. 2024 Aug;
26(8).
PMID: 39202157
We present a Bayesian adaptive design for dose finding in oncology trials with application to a first-in-human trial. The design is based on the escalation with overdose control principle and...
2.
Peipert J, Roydhouse J, Tighiouart M, Henry N, Kim S, Hays R, et al.
Qual Life Res
. 2024 Jul;
33(11):3069-3079.
PMID: 39080091
Purpose: Regulatory guidance suggests capturing patient-reported overall side effect impact in cancer trials. We examined whether the Functional Assessment of Cancer Therapy (FACT) GP5 item ("I am bothered by side...
3.
Luu M, Gresham G, Henry L, Kim S, Rogatko A, Yothers G, et al.
JCO Clin Cancer Inform
. 2024 Jul;
8:e2400007.
PMID: 39013121
Purpose: Longitudinal patient tolerability data collected as part of randomized controlled trials are often summarized in a way that loses information and does not capture the treatment experience. To address...
4.
Tighiouart M, Jimenez J, Diniz M, Rogatko A
Braz J Biom
. 2024 Feb;
40(4):453-468.
PMID: 38357386
In parametric Bayesian designs of early phase cancer clinical trials with drug combinations exploring a discrete set of partially ordered doses, several authors claimed that there is no added value...
5.
Calsavara V, Henry N, Hays R, Kim S, Luu M, Diniz M, et al.
Cancer Prev Res (Phila)
. 2023 Sep;
16(11):631-639.
PMID: 37756580
Prevention Relevance: The dynamic prediction provided by partly conditional models offers valuable insights into the treatment discontinuation risks using PRO data collected over time from clinical trial participants. This tool...
6.
Lyden P, Diniz M, Bosetti F, Lamb J, Nagarkatti K, Rogatko A, et al.
Sci Transl Med
. 2023 Sep;
15(714):eadg8656.
PMID: 37729432
Human diseases may be modeled in animals to allow preclinical assessment of putative new clinical interventions. Recent, highly publicized failures of large clinical trials called into question the rigor, design,...
7.
Wei J, Jalnakupur S, Cruz S, Wiens G, Motwani M, Zhang X, et al.
Cardiovasc Disord Med
. 2023 Mar;
2019.
PMID: 36913201
Background: Stress cardiac magnetic resonance (CMR) imaging with myocardial perfusion reserve index (MPRI) measurement has emerged as a noninvasive method for assessing coronary microvascular dysfunction (CMD) in the absence of...
8.
Henry N, Kim S, Hays R, Diniz M, Tighiouart M, Gresham G, et al.
NPJ Breast Cancer
. 2022 Nov;
8(1):123.
PMID: 36402796
Adjuvant chemotherapy improves breast cancer survival but is associated with bothersome short- and long-term toxicity. Factors associated with toxicity, especially subacute toxicity up to 2 years following chemotherapy, have not...
9.
Calsavara V, Diniz M, Tighiouart M, Ganz P, Henry N, Hays R, et al.
Qual Life Res
. 2022 Oct;
32(3):827-839.
PMID: 36245019
Purpose: Efficient analytical methods are necessary to make reproducible inferences on single-item longitudinal ordinal patient-reported outcome (PRO) data. A thorough simulation study was performed to compare the performance of the...
10.
Ganz P, Hays R, Spritzer K, Rogatko A, Ko C, Colangelo L, et al.
Cancer
. 2022 Jun;
128(17):3233-3242.
PMID: 35749631
Background: There has been limited evaluation of health-related quality of life (HRQOL) in rectal cancer patients receiving neoadjuvant chemoradiotherapy. HRQOL outcomes in the National Surgical Adjuvant Breast and Bowel Project...